Secreted inflammatory cytokines are considered as critical mediators in the tumor microenvironment. Cancer cells play a significant role in the differentiation of effector T cells to exhausted T cells through mediator production. Effector T cells that undergo tumor microenvironment become terminally differentiated into exhausted T cells. These changes create an opportunity for tumorigenesis and invasion of cancer cells. Despite having some characteristics of effector T cells, the exhausted T cells lose their antitumor properties. In this article, the phenotypes and function of exhausted T cells were reviewed and the expression pattern of inflammatory cytokines in tumor tissues and peripheral blood of cancer patients were described. Additionally, the effects of inflammatory cytokines on intracellular factors and signals of T lymphocyte cells were explained. In conclusion, the authors referred to probable approaches that could be used to improve the antitumor activity of T cells and intervention into T cell exhaustion.
Get full access to this article
View all access options for this article.
References
1.
ChowMT, MöllerA, SmythMJ. Inflammation and immune surveillance in cancer. Semin Cancer Biology, 2012; 22:23.
2.
JunttilaMR, de SauvageFJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature, 2013; 501:346.
3.
RamelloMC, BoariJT, CanaleFP, et al.Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell Death Dis, 2014; 5:e1507.
4.
ApetohL, SmythMJ, DrakeCG, et al.Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology, 2015; 4:e998538.
5.
KumariN, DwarakanathBS, DasA, et al.Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol, 2016; 37:11553.
6.
KershawMH, WestwoodJA, DarcyPK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer, 2013; 13:525.
7.
MoonEK, WangL-C, DolfiDV, et al.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors. Clin Cancer Res, 2014; 20:4262.
8.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12:252.
9.
HofmannL, ForschnerA, LoquaiC, et al.Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer, 2016; 60:190.
10.
WherryEJ. T cell exhaustion. Nat Immunol, 2011; 12:492.
11.
JiangY, LiY, ZhuB. T-cell exhaustion in the tumor microenvironment. Cell Death Dis, 2015; 6:e1792.
12.
SenaLA, LiS, JairamanA, et al.Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity, 2013; 38:225.
13.
SchurichA, PallettLJ, JajbhayD, et al.Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep, 2016; 16:1243.
14.
Ghatreh-SamaniM, EsmaeiliN, SoleimaniM, et al.Oxidative stress and age-related changes in T cells: Is thalassemia a model of accelerated immune system aging?. Cent J Immunol, 2016; 41:116.
15.
YokosukaT, TakamatsuM, Kobayashi-ImanishiW, et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med, 2012; 209:1201.
16.
LiC, LiW, XiaoJ, et al.ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy. EMBO Mol Med, 2015; 7:754.
17.
IseW, KohyamaM, SchramlBU, et al.The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol, 2011; 12:536.
18.
WherryEJ, KurachiM. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol, 2015; 15:486.
19.
TaylorA, HarkerJA, ChanthongK, et al.Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8+ cytolytic T cell responses. Immunity, 2016; 44:274.
20.
AndreevK, TrufaIDI, SiegemundR, et al.Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma. Br J Cancer, 2015; 113:902.
21.
EbertPJR, CheungJ, YangY, et al.MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity, 2016; 44:609.
22.
FourcadeJ, SunZ, BenallaouaM, et al.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients. J Exp Med, 2010; 207:2175.
23.
KangC-W, DuttaA, ChangL-Y, et al.Apoptosis of tumor infiltrating effector TIM-3+ CD8+ T cells in colon cancer. Sci Rep, 2015; 5:15659.
24.
KoyamaS, AkbayEA, LiYY, et al.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 2016; 7:10501.
25.
SakuishiK, ApetohL, SullivanJM, et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 2010; 207:2187.
26.
RangachariM, ZhuC, SakuishiK, et al.Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med, 2012; 18:1394.
27.
ChibaS, BaghdadiM, AkibaH, et al.Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol, 2012; 13:832.
28.
PonnusamyK, KohrsN, PtasinskaA, et al.RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis, 2015; 4:e146.
29.
VeermanKM, WilliamsMJ, UchimuraK, et al.Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat Immunol, 2007; 8:532.
30.
TinocoR, CarretteF, BarrazaML, et al.PSGL-1 is an immune checkpoint regulator that promotes T cell exhaustion. Immunity, 2016; 44:1190.
31.
MinerJJ, XiaL, YagoT, et al.Separable requirements for cytoplasmic domain of PSGL-1 in leukocyte rolling and signaling under flow. Blood, 2008; 112:2035.
32.
NeischAL, FehonRG. Ezrin, radixin and moesin: Key regulators of membrane–cortex interactions and signaling. Curr Opin Cell Biol, 2011; 23:377.
33.
CarretteF, SurhCD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol, 2012; 24:209.
34.
VudattuNK, MagalhaesI, SchmidtM, et al.Reduced numbers of IL‐7 receptor (CD127) expressing immune cells and IL‐7‐signaling defects in peripheral blood from patients with breast cancer. Int J Cancer, 2007; 121:1512.
35.
CominoMRS. PD-1 expression profile and phenotypes of peripheral blood T lymphocytes in breast cancer. TE UN MÜNCH. 2011; 12:2.
36.
KaryampudiL, LamichhaneP, ScheidAD, et al.Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res, 2014; 74:2974.
37.
SongG, WangX, JiaJ, et al.Elevated level of peripheral CD8+ CD28− T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother, 2013; 62:1123.
38.
KaragözB, BilgiO, GümüsM, et al.CD8+ CD28− cells and CD4+ CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol, 2010; 27:29.
39.
WolfraimLA, LetterioJJ. Cutting edge: p27Kip1 deficiency reduces the requirement for CD28-mediated costimulation in naive CD8+ but not CD4+ T lymphocytes. J Immunol, 2005; 174:2481.
40.
CruszSM, BalkwillFR. Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol, 2015; 12:584.
HeikkiläK, EbrahimS, LawlorDA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer, 2008; 44:937.
43.
TaniguchiK, KarinM. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol, 2014; 26:54.
44.
CammarotaR, BertoliniV, PennesiG, et al.The tumor microenvironment of colorectal cancer: Stromal TLR-4 expression as a potential prognostic marker. J Transl Med, 2010; 8:112.
45.
LippitzBE. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol, 2013; 14:e218.
46.
BalkwillF. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev, 2006; 25:409.
47.
ElarajDM, WeinreichDM, VargheseS, et al.The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res, 2006; 12:1088.
48.
PerrierS, Caldefie-ChézetF, VassonM-P. IL‐1 family in breast cancer: Potential interplay with leptin and other adipocytokines. FEBS Lett, 2009; 583:259.
49.
ZhangJ-P, YanJ, XuJ, et al.Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol, 2009; 50:980.
50.
ManiatiE, SoperR, HagemannT. Up for Mischief? IL-17/Th17 in the tumour microenviroment. Oncogene, 2010; 29:5653.
51.
MaJ, MaD, JiC. The role of IL-21 in hematological malignancies. Cytokine, 2011; 56:133.
52.
AustinJW, LuP, MajumderP, et al.STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol, 2014; 192:4876.
53.
XinG, SchauderDM, LainezB, et al.A critical role of IL-21-induced BATF in sustaining CD8-T-cell-mediated chronic viral control. Cell Rep, 2015; 13:1118.
54.
MurphyTL, TussiwandR, MurphyKM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol, 2013; 13:499.
55.
BisigB, ThielenC, HerensC, et al.c‐Maf expression in angioimmunoblastic T‐cell lymphoma reflects follicular helper T‐cell derivation rather than oncogenesis. Histopathology, 2012; 60:371.
56.
RutishauserRL, MartinsGA, KalachikovS, et al.Transcriptional repressor Blimp-1 promotes CD8+ T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity, 2009; 31:296.
57.
HerathNI, RocquesN, GarancherA, et al.GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J, 2014; 4:e175.
58.
HossainDMS, PandaAK, MannaA, et al.FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity, 2013; 39:1057.
59.
SimonettaF, ChialiA, CordierC, et al.Increased CD127 expression on activated FOXP3+ CD4+ regulatory T cells. Eur J Immunol, 2010; 40:2528.
60.
IoachimHL, DecusearaR, GiancottiF, et al.FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases. Pathol Pract, 2005; 200:743.
61.
BakkerWJ, HarrisIS, MakTW. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell, 2007; 28:941.
62.
OhH-M, YuC-R, GolestanehN, et al.STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem, 2011; 286:30888.
63.
GattinoniL, KlebanoffCA, RestifoNP. Paths to stemness: Building the ultimate antitumour T cell. Nat Rev Cancer, 2012; 12:671.
64.
YiF, PereiraL, HoffmanJA, et al.Opposing effects of Tcf3 and Tcf1 control Wnt-stimulation of embryonic stem cell self renewal. Nat Cell Biol, 2011; 13:762.
65.
HuarteE, FisherJ, TurkMJ, et al.Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett, 2009; 285:80.
66.
FröhlichA, KisielowJ, SchmitzI, et al.IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science, 2009; 324:1576.
67.
JohnSY, DuM, ZajacAJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science, 2009; 324:1572.
68.
ParishST, WuJE, EffrosRB. Modulation of T lymphocyte replicative senescence via TNF-α inhibition: Role of caspase-3. J Immunol, 2009; 182:4237.
69.
BrylE, VallejoAN, WeyandCM, et al.Down-regulation of CD28 expression by TNF-α. J Immunol, 2001; 167:3231.
70.
HeonEK, WulanH, MacdonaldLP, et al.IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer. Biochem Biophys Res Commun, 2015; 464:360.
71.
AfkarianM, SedyJR, YangJ, et al.T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol, 2002; 3:549.
72.
GoswamiS, SahaiE, WyckoffJB, et al.Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res, 2005; 65:5278.
73.
LiL, KimHT, NelloreA, et al.Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J, 2014; 4:e178.
74.
FlynnJK, GorryPR. Stem memory T cells (TSCM)—Their role in cancer and HIV immunotherapies. Clin Transl Immunol, 2014; 3:e20.
75.
BrouxB, Markovic-PleseS, StinissenP, et al.Pathogenic features of CD4+ CD28– T cells in immune disorders. Trends Mol Med, 2012; 18:446.
76.
HodgeG, JersmannH, TranHB, et al.Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. Respir Res, 2015; 16:130.
77.
YokoyamaY, FukunagaK, IkeuchiH, et al.The CD4+ CD28 null and the regulatory CD4+ CD25 High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, and following colectomy. Cytokine, 2011; 56:466.
78.
Tena JGDe, ManzanoL, LealJC, et al.Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+ CD45RO+ CD28null T cells. J Clin Immunol, 2004; 24:185.
79.
MichelJJ, TuressonC, LemsterB, et al.CD56‐expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheumatol, 2007; 56:43.
80.
SeifF, KhoshmirsafaM, MousaviM, et al.Interleukin-21 receptor might be a novel therapeutic target for the treatment of rheumatoid arthritis. J Exp Clin Med, 2014; 6:57.
81.
BlackburnSD, ShinH, HainingWN, et al.Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol, 2009; 10:29.
82.
LarrubiaJR, LokhandeMU, García‐GarzónS, et al.Persistent hepatitis C virus (HCV) infection impairs HCV‐specific cytotoxic T cell reactivity through Mcl‐1/Bim imbalance due to CD127 down‐regulation. J Viral Hepat, 2013; 20:85.
83.
DirksJ, TasH, SchmidtT, et al.PD-1 analysis on CD28− CD27− CD4 T cells allows stimulation‐independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant, 2013; 13:3132.
84.
BrouxB, PannemansK, ZhangX, et al.CX 3 CR1 drives cytotoxic CD4+ CD28− T cells into the brain of multiple sclerosis patients. J Autoimmun, 2012; 38:10.
85.
KoguchiK, AndersonDE, YangL, et al.Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med, 2006; 203:1413.
86.
KöglT, MüllerJ, JessenB, et al.Hemophagocytic lymphohistiocytosis in syntaxin-11–deficient mice: T-cell exhaustion limits fatal disease. Blood, 2013; 121:604.
87.
Helmin‐BasaA, MichalkiewiczJ, GackowskaL, et al.Pediatric Helicobacter pylori infection and circulating T‐lymphocyte activation and differentiation. Helicobacter, 2011; 16:27.
88.
Azadegan-DehkordiF, BagheriN, ShirzadM, et al.Correlation between mucosal IL-6 mRNA expression level and virulence factors of Helicobacter pylori in Iranian adult patients with chronic gastritis. Jundishapur J Microbiol, 2015; 8:e21701.
89.
BagheriN, Azadegan-DehkordiF, ShirzadM, et al.Mucosal interleukin-21 mRNA expression level is high in patients with Helicobacter pylori and is associated with the severity of gastritis. Cent Eur J Immunol, 2015; 40:61.
